Colorectal cancer-associated lncRNA (CCAL) was identified as modifying the response to adjuvant chemotherapy in CRC patients by inducing multidrug resistance (MDR) through activating WNT/β-catenin signaling by suppressing AP-2α and further upregulating MDR1/P-gp levels [128]. This evidence concerns the gene PGP and colorectal cancer.